JP6700639B2 - 骨粗しょう症の予防及び治療用の置換芳香族化合物ならびに医薬組成物 - Google Patents

骨粗しょう症の予防及び治療用の置換芳香族化合物ならびに医薬組成物 Download PDF

Info

Publication number
JP6700639B2
JP6700639B2 JP2017518905A JP2017518905A JP6700639B2 JP 6700639 B2 JP6700639 B2 JP 6700639B2 JP 2017518905 A JP2017518905 A JP 2017518905A JP 2017518905 A JP2017518905 A JP 2017518905A JP 6700639 B2 JP6700639 B2 JP 6700639B2
Authority
JP
Japan
Prior art keywords
compound
osteoporosis
bone
alkyl
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017518905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530180A5 (enExample
JP2017530180A (ja
Inventor
リン・ギャニオン
ブリジット・グルー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal Biosciences Ltd
Original Assignee
Liminal Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal Biosciences Ltd filed Critical Liminal Biosciences Ltd
Publication of JP2017530180A publication Critical patent/JP2017530180A/ja
Publication of JP2017530180A5 publication Critical patent/JP2017530180A5/ja
Application granted granted Critical
Publication of JP6700639B2 publication Critical patent/JP6700639B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017518905A 2014-10-10 2015-10-08 骨粗しょう症の予防及び治療用の置換芳香族化合物ならびに医薬組成物 Expired - Fee Related JP6700639B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062597P 2014-10-10 2014-10-10
US62/062,597 2014-10-10
PCT/CA2015/000540 WO2016054728A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Publications (3)

Publication Number Publication Date
JP2017530180A JP2017530180A (ja) 2017-10-12
JP2017530180A5 JP2017530180A5 (enExample) 2018-11-22
JP6700639B2 true JP6700639B2 (ja) 2020-05-27

Family

ID=55652429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518905A Expired - Fee Related JP6700639B2 (ja) 2014-10-10 2015-10-08 骨粗しょう症の予防及び治療用の置換芳香族化合物ならびに医薬組成物

Country Status (23)

Country Link
US (2) US20180228750A1 (enExample)
EP (1) EP3203999B1 (enExample)
JP (1) JP6700639B2 (enExample)
KR (1) KR20170066476A (enExample)
CN (1) CN106999456B (enExample)
AR (1) AR102246A1 (enExample)
AU (1) AU2015330645B2 (enExample)
BR (1) BR112017007426A2 (enExample)
CA (1) CA2963354A1 (enExample)
DK (1) DK3203999T3 (enExample)
ES (1) ES2785317T3 (enExample)
IL (1) IL251404B (enExample)
MX (1) MX376873B (enExample)
MY (1) MY194308A (enExample)
PH (1) PH12017500638A1 (enExample)
PL (1) PL3203999T3 (enExample)
PT (1) PT3203999T (enExample)
RU (1) RU2709205C2 (enExample)
SG (1) SG11201702868VA (enExample)
TW (1) TWI699200B (enExample)
UY (1) UY36356A (enExample)
WO (1) WO2016054728A1 (enExample)
ZA (1) ZA201702639B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054725A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
AU2015345943B2 (en) * 2014-11-12 2020-03-19 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20190065252A (ko) * 2016-08-18 2019-06-11 인테크린 테라퓨틱스, 아이엔씨. 골 질환 치료용 PPARγ 작용제
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
AU2021356346A1 (en) * 2020-10-06 2023-06-15 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
MX2024005982A (es) * 2021-11-17 2024-05-30 Natreon Inc Withania somnifera y asparagus racemosus en el tratamiento de enfermedades posmenopausicas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200720256A (en) * 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
EP2427416B1 (en) * 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
BRPI1015118A2 (pt) * 2009-05-04 2016-04-12 Prometic Biosciences Inc sais de ácido pentilfenilacético e usos farmacêuticos dos mesmos
PH12013500763B1 (en) * 2010-10-27 2018-07-04 Prometic Pharma Smt Ltd Phenylketone carboxylate compounds and pharmaceutical uses thereof
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
WO2016054725A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Also Published As

Publication number Publication date
AR102246A1 (es) 2017-02-15
KR20170066476A (ko) 2017-06-14
BR112017007426A2 (pt) 2018-01-16
CA2963354A1 (en) 2016-04-14
MY194308A (en) 2022-11-27
TW201618762A (zh) 2016-06-01
IL251404B (en) 2020-11-30
WO2016054728A1 (en) 2016-04-14
IL251404A0 (en) 2017-05-29
PT3203999T (pt) 2020-04-23
EP3203999B1 (en) 2020-01-08
RU2017116178A (ru) 2018-11-19
DK3203999T3 (da) 2020-03-30
ZA201702639B (en) 2018-06-27
PL3203999T3 (pl) 2020-07-27
UY36356A (es) 2016-06-01
US11185521B2 (en) 2021-11-30
AU2015330645B2 (en) 2020-03-12
PH12017500638A1 (en) 2017-09-25
AU2015330645A1 (en) 2017-05-04
CN106999456B (zh) 2020-07-10
SG11201702868VA (en) 2017-05-30
RU2709205C2 (ru) 2019-12-17
MX2017004733A (es) 2017-07-17
ES2785317T3 (es) 2020-10-06
CN106999456A (zh) 2017-08-01
JP2017530180A (ja) 2017-10-12
EP3203999A4 (en) 2018-06-27
EP3203999A1 (en) 2017-08-16
MX376873B (es) 2025-03-07
TWI699200B (zh) 2020-07-21
RU2017116178A3 (enExample) 2019-05-16
US20200237693A1 (en) 2020-07-30
US20180228750A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
US11185521B2 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
KR101821646B1 (ko) 암을 치료하기 위한 화합물 및 조성물
CN101434517A (zh) 治疗免疫疾病的新的1,2-二苯基乙烯衍生物
CN1993120B (zh) 用于治疗阿尔茨海默氏病的芳基乙酸和相关化合物
KR20170066614A (ko) 당뇨병의 예방 및 치료를 위한 치환된 방향족 화합물 및 약제학적 조성물
JP6700638B2 (ja) 骨粗しょう症の予防及び治療用のフェニルケトンカルボキシレート化合物ならびに医薬組成物
HK1236420A1 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
HK1236420B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
CN101768133A (zh) 二苯基乙烯类衍生物及其用途
HK1236419B (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
HK1236419A1 (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
HK1227740B (en) Compounds and compositions for the treatment of cancer
HK1227740A (en) Compounds and compositions for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200421

R150 Certificate of patent or registration of utility model

Ref document number: 6700639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees